SG Americas Securities
KLRS

SG Americas Securities’s Kalaris Therapeutics KLRS Stock Holding History

SG Americas Securities’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-765
Closed -$13K – 3389
2024
Q1 		$13K Buy
765
+13
+2% +$212 ﹤0.01% 2885
2023
Q4 		$12K Sell
752
-261
-26% -$10.3K ﹤0.01% 3031
2023
Q3 		$50K Buy
+1,013
New +$69K ﹤0.01% 2944
2023
Q2 		– Sell
-708
Closed -$64K – 3309
2023
Q1 		$64K Buy
708
+167
+31% +$21.3K ﹤0.01% 3025
2022
Q4 		$64K Buy
541
+1
+0.2% +$170 ﹤0.01% 2809
2022
Q3 		$98K Sell
540
-11
-2% -$1.71K ﹤0.01% 2864
2022
Q2 		$49K Buy
+551
New +$57.8K ﹤0.01% 3265
2021
Q4 		– Sell
-663
Closed -$382K – 3875
2021
Q3 		$382K Buy
663
+169
+34% +$78.3K ﹤0.01% 2738
2021
Q2 		$224K Buy
494
+48
+11% +$24.8K ﹤0.01% 2287
2021
Q1 		$240K Buy
+446
New +$375K ﹤0.01% 2552

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG Americas Securities's KLRS Position: Q2 2024 in Review

SG Americas Securities sold out of Kalaris Therapeutics (KLRS) in Q2 2024, closing a stake of 765 shares — an estimated $13K sold.

SG Americas Securities first reported a position in KLRS in Q1 2021 and held it in 10 quarters. The position peaked at $382K in Q3 2021. 71 funds tracked by Wall St. Rank hold KLRS as of Q2 2024.

  • SG Americas Securities reported no remaining Kalaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • SG Americas Securities sold 765 Kalaris Therapeutics shares in Q2 2024, an estimated $13K.
  • SG Americas Securities first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 10 quarters.
  • SG Americas Securities's Kalaris Therapeutics position peaked at $382K in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2024.

Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.